Nasal Polyps Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Nasal Polyps Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Report Format: PDF+Excel | Report ID: SR112024A7725
Buy Now

Market Overview: 

The 7 major nasal polyps markets reached a value of US$ 68.6 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 109.0 Million by 2034, exhibiting a growth rate (CAGR) of 4.3% during 2024-2034.

Report Attribute
Key Statistics
Base Year
2023
Forecast Years 2024-2034
Historical Years
2018-2023
Market Size in 2023
US$ 68.6 Million
Market Forecast in 2034
US$ 109.0 Million
Market Growth Rate (2024-2034)
4.3%


The nasal polyps market has been comprehensively analyzed in IMARC's new report titled "Nasal Polyps Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Nasal polyps refer to a medical condition in which there are soft, painless growths on the lining of the nasal passage or sinuses. They are noncancerous and often occur in the area where the sinuses open into the nasal cavity. Nasal polyps can be single or multiple and vary in size from small to large. The common symptoms of this ailment include a runny nose, persistent stuffiness, postnasal drip, decreased or absent sense of smell, facial pain, frequent nosebleeds, headache, snoring, pain in the upper teeth, a sense of pressure over the forehead and face, etc. The diagnosis of the illness is typically based on the patient’s medical history, clinical features, and a general physical test. Nasal endoscopy is further recommended in patients for a detailed examination of the nose and sinuses. The healthcare professional may also perform imaging studies, such as a computerized tomography (CT) scan, to evaluate the location and size of polyps in deeper areas of the sinuses and rule out other possible blockages in the nasal cavity.

Nasal Polyps Market

The rising cases of allergies or infections, which trigger long-term inflammation and irritation in the nasal passage, are primarily driving the nasal polyps market. Moreover, the increasing incidence of genetic mutations associated with immune system functioning that result in the formation of abnormally thick, sticky mucus from the nasal and sinus linings is also bolstering the market growth. In addition to this, the widespread adoption of intranasal corticosteroid injections, like fluticasone, over conventional oral drugs on account of their improved efficacy profiles and lower risk of systemic side effects, is acting as another significant growth-inducing factor. Furthermore, the escalating demand for image guided endoscopic sinus surgery, which helps to improve precision, reduce complications, and enhance surgical outcomes in patients, is also creating a positive outlook for the market. Additionally, the rising popularity of biological drugs for treating the ailment, as they work by targeting specific proteins or cells to reduce swelling and irritation in the nasal passage, is expected to drive the nasal polyps market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the nasal polyps market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for nasal polyps and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the nasal polyps market in any manner.

Key Highlights:

  • Approximately 4% of people currently have nasal polyps, and up to 40% will develop them at some point in their lives.
  • There are two forms of nasal polyps, including ethmoidal and antrochoanal.
  • Antrochoanal polyps mainly develop in the maxillary sinus and spread into the nasopharynx, accounting for only 4-6% of total nasal polyps.
  • In the United States, chronic rhinosinusitis with nasal polyposis (CRSwNP) typically affects patients aged 40 to 60 years.
  • Males are more inclined to have CRSwNP, with one study reporting a 38% incidence in females and a 62% prevalence in males.
  • The prevalence of CRSwNP is estimated to be around 1.1% in the United States, whereas estimates in Europe range from 2.1% to 4.4%.


Drugs:

DUPIXENT is a prescription therapy used with additional medicines to maintain the treatment of CRSwNP in individuals whose condition is not under control. It works by blocking two key sources of type 2 inflammation, shrinking nasal polyps, and minimizing the need for surgery.

Benralizumab is a monoclonal antibody that attracts natural killer cells through antibody-dependent cellular cytotoxicity activity (ADCC activity), resulting in direct and rapid eosinophil reduction in the blood and airways. It is offered as a fixed-dose subcutaneous injection via a prefilled syringe delivered once every four weeks for the initial 3 doses and once every eight weeks thereafter.

ACT-774312 is referred to as an antagonist of the chemoattractant receptor-homologous molecule expressed on T helper (Th) 2 cells (CRTH2) that is being developed for the treatment of nasal polyposis and other allergy and inflammatory illnesses.


Time Period of the Study

  • Base Year: 2023
  • Historical Period: 2018-2023
  • Market Forecast: 2024-2034
     

Countries Covered

  • United States
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Japan
     

Analysis Covered Across Each Country

  • Historical, current, and future epidemiology scenario
  • Historical, current, and future performance of the nasal polyps market
  • Historical, current, and future performance of various therapeutic categories in the market
  • Sales of various drugs across the nasal polyps market
  • Reimbursement scenario in the market
  • In-market and pipeline drugs


Competitive Landscape:

This report also provides a detailed analysis of the current nasal polyps marketed drugs and late-stage pipeline drugs.

In-Market Drugs

  • Drug Overview
  • Mechanism of Action
  • Regulatory Status
  • Clinical Trial Results
  • Drug Uptake and Market Performance
     

Late-Stage Pipeline Drugs

  • Drug Overview
  • Mechanism of Action
  • Regulatory Status
  • Clinical Trial Results
  • Drug Uptake and Market Performance
     
Drugs Company Name
Dupixent (Dupilumab) Regeneron/Sanofi
Nucala (Mepolizumab) GlaxoSmithKline
Xolair (Omalizumab) Genentech/Novartis
Xhance (Fluticasone propionate intranasal) OptiNose
Benralizumab AstraZeneca/Kyowa Kirin
ACT 774312 Idorsia Pharmaceuticals Ltd.


*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.


Key Questions Answered in this Report:

Market Insights

  • How has the nasal polyps market performed so far and how will it perform in the coming years?
  • What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
  • What was the country-wise size of the nasal polyps market across the seven major markets in 2023 and what will it look like in 2034?
  • What is the growth rate of the nasal polyps market across the seven major markets and what will be the expected growth over the next ten years?
  • What are the key unmet needs in the market?
     

Epidemiology Insights

  • What is the number of prevalent cases (2018-2034) of nasal polyps across the seven major markets?
  • What is the number of prevalent cases (2018-2034) of nasal polyps by age across the seven major markets?
  • What is the number of prevalent cases (2018-2034) of nasal polyps by gender across the seven major markets?
  • How many patients are diagnosed (2018-2034) with nasal polyps across the seven major markets?
  • What is the size of the nasal polyps patient pool (2018-2023) across the seven major markets?
  • What would be the forecasted patient pool (2024-2034) across the seven major markets?
  • What are the key factors driving the epidemiological trend of nasal polyps?
  • What will be the growth rate of patients across the seven major markets?
     

Nasal Polyps: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

  • What are the current marketed drugs and what are their market performance?
  • What are the key pipeline drugs and how are they expected to perform in the coming years?
  • How safe are the current marketed drugs and what are their efficacies?
  • How safe are the late-stage pipeline drugs and what are their efficacies?
  • What are the current treatment guidelines for nasal polyps drugs across the seven major markets?
  • Who are the key companies in the market and what are their market shares?
  • What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the nasal polyps market?
  • What are the key regulatory events related to the nasal polyps market?
  • What is the structure of clinical trial landscape by status related to the nasal polyps market?
  • What is the structure of clinical trial landscape by phase related to the nasal polyps market?
  • What is the structure of clinical trial landscape by route of administration related to the nasal polyps market?

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
Nasal Polyps Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
Purchase options




Benefits of Customization

Personalize this research

Triangulate with your data

Get data as per your format and definition

Gain a deeper dive into a specific application, geography, customer, or competitor

Any level of personalization

Get in Touch With Us
UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-714-6104

Email: sales@imarcgroup.com

Client Testimonials

Aktive Services

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

Read More
Greenfish S.A.

The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required

Read More
Colruyt Group

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Read More
KRISHAK BHARTI CO-OP LTD

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

Read More
Zee Media Corp. Ltd.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Read More
Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

Read More
Sumitomo Corporation

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

Read More
Hameln Rds

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

Read More
Quality Consultants BV

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

Read More
TATA Advanced Systems Limited

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

Read More
Stax

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.

Read More